Popular Articles

Blogs Comment On Planned Parenthood Ad Campaign, Sex-Selective Abortion, Other Topics
The following summarizes selected women"s health-related blog entries.~ "A Radical Notion: Women"s Health Care as Mainstream," Cecile Richards, Huffington Post blogs: "To hammer ... home" the message that "Planned Parenthood and other essential community providers are the affordable, local access to basic preventive care that saves lives," the Planned Parenthood Action Center has introduced advertisements "educating the policy folks involved in fixing our health care system" about "why women"s health care needs to be taken care of in this mega-reform effort," Richards writes. She writes, "From cancer screenings to contraception to immunizations, the majority of women who go to women"s health care centers consider them their primary health care provider," adding, "In fact, more than 90% of what Planned Parenthood health centers do is preventive and primary care." According to Richards, "Essential community providers, including those who provide women"s health care, need to be part of any newly established health care system." She adds that "the three million patients who came to Planned Parenthood health centers last year can testify to it." Richards writes that "[f]amily planning and reproductive health care are unfortunately still not fully part of mainstream health care, even though 98% of women use contraception at some point in their lives -- there"s nothing more universal!" The "fact that women reproduce and, therefore, have different types of health care needs makes some folks on Capitol Hill go pale and start to sweat," Richards writes. She concludes, "Maybe one day we won"t need a special campaign to support women"s health," but "until then, Planned Parenthood is here to make sure women aren"t worse off after health care reform than before" (Richards, Huffington Post blogs, 6/18).~ "The Role of Medical Education in Preserving Abortion Access," Our Bodies, Our Blog: In response to a recent Salon opinion piece that examined whether there will be a next generation of abortion providers, the blog post discusses a few organizations that are "working to increase access to (accurate) abortion-related training." The blog includes links to Medical Students for Choice -- a group that "does student organizing and advocacy to influence medical school curricula, workshops ... and lectures on abortion techniques" -- and The Ryan Program -- which offers "funding, technical expertise, curriculum, workshops and other res to support training opportunities in abortion and contraception for ob-gyn residents." The blog entry also highlights the work of Physicians for Reproductive Choice and Health, which partners with members of the American Medical Student Association "to provide "project in a box" materials for medical students wanting to access and influence their schools" curricula on sexual and reproductive health" (Our Bodies, Our Blog, 6/18). ~ "Regulating Abortion May Be OK But Not To Avoid Sex-Selection," Marianne Mollmann, Huffington Post blogs: "Sex-selective abortion raises a multitude of overlapping ethical concerns regarding eugenics, population control and provider privilege or knowledge," according to Mollmann, advocacy director for the Human Rights Watch"s Women"s Rights Division. Mollmann writes that recent media reports indicating that sex-selective abortion occurs among some ethnic communities in the U.S. "has generated new discussion about what to do -- indeed what to think -- about the practice here." She continues that the "effect of abortion regulations depends on the context and motivation," adding that "[f]rom a human rights perspective, the regulation of medical procedures and interventions is legitimate and indeed often necessary so long as they are based on full respect for the full range of human rights." It is "perhaps tempting to hope that banning sex-selective abortions would safeguard the gender balance of future generations," but the "criminalization of abortion for whatever reason has in the past led only to underground and unsafe prac

Expanded Testing Reveals 2000 Percent Increase In Number Of HIV-Positive Indian Children
"Expanded testing across India in the past three years shows a 2,000 percent jump in the number of HIV cases among children, [Ghulam Nabi Azad] the country"s health minister announced Wednesday," CNN reports. As of May 2009, reports found that nearly 53,000 children are living with HIV in India - up from 2,253 recorded cases in November 2006, Azad said during an address to the parliament (Singh, 7/29).
News of the day
BJOG Release: New Study On The Cause Of Early Preterm Birth
An exploratory study to be published in BJOG: An International Journal of Obstetrics and Gynaecology, has shown that women going into early preterm labour (before 34 weeks gestation) have low-levels of progesterone in their saliva as early as 24 weeks, and that moreover, these levels fail to rise during pregnancy in the normal way. This offers the possibility of developing a simple, non-invasive test to identify women at increased risk of delivering early.
Mental Health

FDA Approves Cambia™ For Migraine

Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. Food and Drug Administration (FDA) has approved Cambia™, a diclofenac-based non-steroidal anti-inflammatory drug ("NSAID") combined with potassium bicarbonate, for the treatment of acute migraine with or without aura in adults. Cambia™, formulated with KPA"s patented Dynamic Buffering Technology (DBT), was specifically developed to address widespread unmet needs among patients by offering fast and effective relief of migraine pain. In randomized clinical trials, Cambia™ was shown to be effective not only in migraine pain, but also in treating photophobia (sensitivity to light), phonophobia (sensitivity to sound), and nausea commonly associated with migraine attacks. Cambia™ was also shown to provide statistically significant onset of relief of migraine pain within 15 to 30 minutes. "The approval is the culmination of over three years of effort from our partners at Applied Pharma Research and the internal team at Kowa," said William Maichle, Chief Operating Officer of Kowa Pharmaceuticals America, Inc. "Patients and physicians consistently mention rapid pain relief as most important when asked about primary attributes of a migraine medication. We believe Cambia™ addresses these needs and will be a valuable addition to physicians" migraine armamentarium." KPA obtained exclusive U.S. and Canadian marketing rights for Cambia™ from Applied Pharma Research (APR), a Swiss drug delivery and drug development company, in 2005. The product is currently marketed by Novartis Pharma AG, via a license from APR, under the trademarks Voltfast or Catafast in several European countries. KPA and APR have been granted patents that cover Cambia™ through 2026. KPA and APR are currently in the final stages of negotiations with a marketing partner and expect Cambia™ to launch in 4th quarter 2009. About Migraine Migraine headaches affect an estimated 30 million people in the United States and disproportionately affect women 3 to 1. According to a recent peer reviewed publication authored by leading migraine researchers, more than 70 percent of patients indicated that they were less than completely satisfied with their current treatment. Over 85 percent complained that pain relief took too long and 25 percent decided to stop seeking treatment altogether. Kowa Company Ltd. Kowa Pharmaceuticals America, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):